US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
ES2241710T3
(es)
|
1991-11-25 |
2005-11-01 |
Enzon, Inc. |
Procedimiento para producir proteinas multivalentes de union a antigeno.
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
AU725609C
(en)
|
1995-08-18 |
2002-01-03 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
DE19629378A1
(de)
|
1996-07-20 |
1998-01-29 |
Boehringer Ingelheim Kg |
Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CA2284737C
(en)
|
1997-03-24 |
2007-03-13 |
Kyowa Hakko Kogyo Co., Ltd. |
[1,2,4]triazolo[1,5-c]pyrimidine derivatives
|
ES2342240T3
(es)
|
1998-08-11 |
2010-07-02 |
Novartis Ag |
Derivados de isoquinolina con actividad que inhibe la angiogenia.
|
BR9914040A
(pt)
|
1998-09-22 |
2002-01-15 |
Kyowa Hakko Kogyo Kk |
Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
AU777970C
(en)
|
1999-05-07 |
2006-08-17 |
F. Hoffman-La Roche Ag |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
WO2001014556A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Novel b7-4 molecules and uses therefor
|
US6355653B1
(en)
|
1999-09-06 |
2002-03-12 |
Hoffmann-La Roche Inc. |
Amino-triazolopyridine derivatives
|
WO2001039722A2
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
US6803192B1
(en)
|
1999-11-30 |
2004-10-12 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
CN101130078A
(zh)
|
2000-04-25 |
2008-02-27 |
拜奥根Idec公司 |
瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
|
WO2001092264A1
(en)
|
2000-05-26 |
2001-12-06 |
Schering Corporation |
Adenosine a2a receptor antagonists
|
PT1294358E
(pt)
|
2000-06-28 |
2004-12-31 |
Smithkline Beecham Plc |
Processo de moagem por via humida
|
ES2320421T3
(es)
|
2001-01-17 |
2009-05-22 |
Intreat Pty Limited |
Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones.
|
AU2002258941A1
(en)
|
2001-04-20 |
2002-11-05 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
JP2004536807A
(ja)
|
2001-05-30 |
2004-12-09 |
アルテオン インコーポレイテッド |
緑内障vの治療方法
|
CA2448306A1
(en)
|
2001-05-30 |
2002-12-05 |
Alteon Inc. |
Method for treating fibrotic diseases or other indications
|
CN100391958C
(zh)
|
2001-09-19 |
2008-06-04 |
安万特医药股份有限公司 |
化合物
|
CA2430328A1
(en)
|
2001-09-28 |
2003-04-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Receptor antagonist
|
WO2003031587A2
(en)
|
2001-10-09 |
2003-04-17 |
The Regents Of The University Of California |
Use of stat-6 inhibitors as therapeutic agents
|
KR20090087139A
(ko)
|
2001-10-30 |
2009-08-14 |
노파르티스 아게 |
Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
TW200300686A
(en)
|
2001-11-30 |
2003-06-16 |
Schering Corp |
Adenosine A2a receptor antagonists
|
NZ534069A
(en)
|
2002-01-22 |
2007-03-30 |
Warner Lambert Co |
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
|
JPWO2003068776A1
(ja)
|
2002-02-15 |
2005-06-02 |
協和醗酵工業株式会社 |
[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
CA2500228A1
(en)
|
2002-09-24 |
2004-04-08 |
Kyowa Hakko Kogyo Co., Ltd. |
[1,2,4]-triazolo[1,5-c]pyrimidine derivative
|
CL2003002353A1
(es)
|
2002-11-15 |
2005-02-04 |
Vertex Pharma |
Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
MXPA05006828A
(es)
|
2002-12-23 |
2005-09-08 |
Wyeth Corp |
Anticuerpos contra pd-1, y sus usos.
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
CA2510003A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
JP4736043B2
(ja)
|
2003-03-14 |
2011-07-27 |
小野薬品工業株式会社 |
含窒素複素環誘導体およびそれらを有効成分とする薬剤
|
TW200505902A
(en)
|
2003-03-20 |
2005-02-16 |
Schering Corp |
Cannabinoid receptor ligands
|
EP1633756B1
(en)
|
2003-04-09 |
2008-12-24 |
Biogen Idec MA Inc. |
A2a adenosine receptor antagonists
|
WO2004092177A1
(en)
|
2003-04-09 |
2004-10-28 |
Biogen Idec Ma Inc. |
Triazolopyrazines and methods of making and using the same
|
US20040202658A1
(en)
|
2003-04-09 |
2004-10-14 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
|
EP1618109A2
(en)
|
2003-04-09 |
2006-01-25 |
Biogen Idec MA Inc. |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
DE602004029160D1
(ru)
|
2003-06-10 |
2010-10-28 |
Kyowa Hakko Kirin Co Ltd |
|
NZ544486A
(en)
|
2003-06-13 |
2009-04-30 |
Biogen Idec Inc |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
KR100742014B1
(ko)
|
2003-08-14 |
2007-07-23 |
에프. 호프만-라 로슈 아게 |
Gaba계 조절제
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
AU2004268621C1
(en)
|
2003-08-29 |
2011-08-18 |
Exelixis, Inc. |
c-Kit modulators and methods of use
|
PE20050952A1
(es)
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
GB0403819D0
(en)
|
2004-02-20 |
2004-03-24 |
Merck Sharp & Dohme |
New compounds
|
JP2007529496A
(ja)
|
2004-03-19 |
2007-10-25 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
JP2008501714A
(ja)
|
2004-06-04 |
2008-01-24 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼインヒビター
|
US7745437B2
(en)
|
2004-06-10 |
2010-06-29 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
US20060040944A1
(en)
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
MXPA06014637A
(es)
|
2004-06-25 |
2007-02-12 |
Amgen Inc |
Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades.
|
US7713973B2
(en)
|
2004-10-15 |
2010-05-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
WO2006044717A2
(en)
|
2004-10-15 |
2006-04-27 |
Verisign, Inc. |
One time password
|
US20060211739A1
(en)
|
2005-02-08 |
2006-09-21 |
Arturo Perez-Medrano |
Use of selective P2X7 receptor antagonists
|
SI2161336T1
(sl)
|
2005-05-09 |
2013-11-29 |
Ono Pharmaceutical Co., Ltd. |
Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
|
KR20080025066A
(ko)
|
2005-05-18 |
2008-03-19 |
바이오겐 아이덱 인크. |
섬유성 상태의 치료 방법
|
WO2006129626A1
(ja)
|
2005-05-30 |
2006-12-07 |
Kyowa Hakko Kogyo Co., Ltd. |
[1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
|
ATE556712T1
(de)
|
2005-06-07 |
2012-05-15 |
Kyowa Hakko Kirin Co Ltd |
A2a antagonisten zur behandlung von motorischen störungen
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
JP4986451B2
(ja)
|
2005-06-30 |
2012-07-25 |
信一郎 礒部 |
マーキング剤
|
BRPI0613361A2
(pt)
|
2005-07-01 |
2011-01-04 |
Medarex Inc |
anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
|
WO2007011759A2
(en)
|
2005-07-15 |
2007-01-25 |
Kalypsys, Inc. |
Inhibitors of mitotic kinesin
|
EP1928237A4
(en)
|
2005-09-02 |
2011-03-09 |
Abbott Lab |
NEW HETEROCYCLES BASED ON IMIDAZO
|
RU2008122967A
(ru)
|
2005-11-10 |
2009-12-20 |
Шеринг Корпорейшн (US) |
Имидазопиразины в качестве ингибиторов протеинкиназ
|
BRPI0618622A2
(pt)
|
2005-11-17 |
2011-09-06 |
Osi Pharm Inc |
composto, composição, e, uso de um composto
|
KR20080077652A
(ko)
|
2005-12-22 |
2008-08-25 |
알콘 리서치, 리미티드 |
로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진
|
WO2007110868A2
(en)
|
2006-03-28 |
2007-10-04 |
Atir Holding S.A. |
Heterocyclic compounds and uses thereof in the treatment of sexual disorders
|
ATE465164T1
(de)
|
2006-05-31 |
2010-05-15 |
Galapagos Nv |
Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
|
WO2007143434A2
(en)
|
2006-05-31 |
2007-12-13 |
Takeda San Diego, Inc. |
Indazole and isoindole derivatives as glucokinase activating agents
|
EP2037905B1
(en)
|
2006-06-23 |
2013-05-01 |
Radius Health, Inc. |
Treatment of vasomotor symptoms with selective estrogen receptor modulators
|
BRPI0713619A2
(pt)
|
2006-06-23 |
2013-01-15 |
Incyte Corp |
composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto.
|
EP2078732B1
(en)
|
2006-07-10 |
2015-09-16 |
Fujita Health University |
Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
|
EP1889846A1
(en)
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
US20080021217A1
(en)
|
2006-07-20 |
2008-01-24 |
Allen Borchardt |
Heterocyclic inhibitors of rho kinase
|
DE102006041292A1
(de)
|
2006-09-01 |
2008-03-06 |
Henkel Kgaa |
Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
|
WO2008037607A1
(de)
|
2006-09-25 |
2008-04-03 |
Basf Se |
Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
|
WO2008056176A1
(en)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines as phosphodiesterase inhibitors
|
WO2008070599A1
(en)
|
2006-12-05 |
2008-06-12 |
Chung-Ming Sun |
Indazole compounds
|
DE102007012645A1
(de)
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
NZ580394A
(en)
|
2007-04-10 |
2011-10-28 |
Lundbeck & Co As H |
Heteroaryl amide analogues as p2x7 antagonists
|
US8039505B2
(en)
|
2007-04-11 |
2011-10-18 |
University Of Utah Research Foundation |
Compounds for modulating T-cells
|
US8133895B2
(en)
|
2007-05-10 |
2012-03-13 |
Janssen Pharmaceutica N.V. |
Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
US20110206607A1
(en)
|
2007-05-10 |
2011-08-25 |
Roger Olsson |
Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
|
HUP0700395A2
(en)
|
2007-06-07 |
2009-03-02 |
Sanofi Aventis |
Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
|
EP2535354B1
(en)
|
2007-06-18 |
2017-01-11 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
US8053574B2
(en)
|
2007-07-18 |
2011-11-08 |
Novartis Ag |
Organic compounds
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
AU2008287421A1
(en)
|
2007-08-10 |
2009-02-19 |
Glaxosmithkline Llc |
Nitrogen containing bicyclic chemical entities for treating viral infections
|
US8062852B2
(en)
|
2007-10-01 |
2011-11-22 |
The Children's Hospital And Regional Medical Center |
Detection and treatment of autoimmune disorders
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
AU2008313727A1
(en)
|
2007-10-18 |
2009-04-23 |
Novartis Ag |
CSF-1R inhibitors for treatment of cancer and bone diseases
|
US20090118301A1
(en)
|
2007-11-02 |
2009-05-07 |
Arbor Vita Corporation |
Compositions and Methods for Treating Cancer
|
WO2009061856A1
(en)
|
2007-11-09 |
2009-05-14 |
The Salk Instituite For Biological Studies |
Non-nucleoside reverse transcriptase inhibitors
|
PE20091074A1
(es)
|
2007-12-13 |
2009-07-26 |
Bayer Healthcare Ag |
Triazolotriazinas y triazolopirazinas y su uso
|
MX2010006457A
(es)
|
2007-12-19 |
2010-07-05 |
Amgen Inc |
Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
|
CA2710194C
(en)
|
2007-12-19 |
2014-04-22 |
Amgen Inc. |
Inhibitors of p13 kinase
|
US8222259B2
(en)
|
2008-03-04 |
2012-07-17 |
Schering Corporation |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
WO2009117421A2
(en)
|
2008-03-17 |
2009-09-24 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
CN102037157B
(zh)
|
2008-03-21 |
2014-05-28 |
恩索恩公司 |
用多官能化合物促进金属对层压板的粘合力
|
US20090281089A1
(en)
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
JPWO2009128520A1
(ja)
|
2008-04-18 |
2011-08-04 |
塩野義製薬株式会社 |
Pi3k阻害活性を有する複素環化合物
|
TWI473614B
(zh)
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
CN102105168A
(zh)
|
2008-07-23 |
2011-06-22 |
协和发酵麒麟株式会社 |
偏头痛治疗剂
|
WO2010032874A1
(ja)
|
2008-09-19 |
2010-03-25 |
住友化学株式会社 |
農業用組成物
|
US20120021519A1
(en)
|
2008-09-19 |
2012-01-26 |
Presidents And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
RU2505540C2
(ru)
|
2008-12-23 |
2014-01-27 |
Эббви Инк. |
Антивирусные соединения
|
EP2367823A1
(en)
|
2008-12-23 |
2011-09-28 |
Abbott Laboratories |
Anti-viral compounds
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
KR20100101056A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
US8846673B2
(en)
*
|
2009-08-11 |
2014-09-30 |
Bristol-Myers Squibb Company |
Azaindazoles as kinase inhibitors and use thereof
|
CN105078978A
(zh)
|
2009-08-17 |
2015-11-25 |
因特利凯公司 |
杂环化合物及其用途
|
US20110105541A1
(en)
|
2009-10-29 |
2011-05-05 |
Jackson Paul F |
ALKYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
|
EP2509983B1
(en)
|
2009-11-16 |
2014-09-17 |
Merck Sharp & Dohme Corp. |
FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2011078143A1
(ja)
|
2009-12-22 |
2011-06-30 |
塩野義製薬株式会社 |
ピリミジン誘導体およびそれらを含有する医薬組成物
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
US20110190269A1
(en)
|
2010-02-01 |
2011-08-04 |
Karlheinz Baumann |
Gamma secretase modulators
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
TW201200518A
(en)
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
MX345762B
(es)
|
2010-03-18 |
2017-02-15 |
Pasteur Institut Korea |
Compuestos antiinfecciosos.
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
GB201007187D0
(en)
|
2010-04-29 |
2010-06-09 |
Iti Scotland Ltd |
Ubiquitination modulators
|
WO2011153588A1
(en)
|
2010-06-10 |
2011-12-15 |
Biota Scientific Management Pty Ltd |
Viral polymerase inhibitors
|
US20120083498A1
(en)
|
2010-06-17 |
2012-04-05 |
Fatah Kashanchi |
Modulators of Viral Transcription, and Methods and Compositions Therewith
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US9023851B2
(en)
|
2010-08-27 |
2015-05-05 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
HUE030714T2
(en)
|
2010-10-25 |
2017-05-29 |
G1 Therapeutics Inc |
CDK inhibitors
|
DK2835131T3
(en)
|
2010-12-14 |
2017-12-04 |
Electrophoretics Ltd |
Casein kinase 1 delta inhibitors (CK1 delta)
|
US8765760B2
(en)
|
2011-01-11 |
2014-07-01 |
Sunovion Pharmaceuticals, Inc. |
[1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
EP2688887B1
(en)
|
2011-03-23 |
2015-05-13 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
KR20140093610A
(ko)
|
2011-04-21 |
2014-07-28 |
재단법인 한국파스퇴르연구소 |
소염 화합물
|
WO2012147890A1
(ja)
|
2011-04-27 |
2012-11-01 |
持田製薬株式会社 |
新規アゾール誘導体
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
EP2604265A1
(en)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
P2x7 antagonists as frontline or adjunctive treatment against status epilepticus
|
WO2013106254A1
(en)
|
2012-01-11 |
2013-07-18 |
Dow Agrosciences Llc |
Pesticidal compositions and processes related thereto
|
CA2868240A1
(en)
|
2012-05-30 |
2013-12-05 |
F. Hoffmann-La Roche Ag |
Triazolo compounds as pde10 inhibitors
|
CN104395298A
(zh)
|
2012-06-22 |
2015-03-04 |
住友化学株式会社 |
稠合杂环化合物
|
RU2015104103A
(ru)
|
2012-07-27 |
2016-09-20 |
Биал - Портела Энд К, С.А. |
Способ синтеза замещенных соединений мочевины
|
WO2014078479A2
(en)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
|
WO2014126580A1
(en)
|
2013-02-15 |
2014-08-21 |
Dow Agrosciences Llc |
Pesticidal compositions and processes related thereto
|
EP2968304B1
(en)
|
2013-03-14 |
2018-10-10 |
The Trustees of Columbia University in the City of New York |
4-phenylpiperidines, their preparation and use
|
US9090697B2
(en)
|
2013-03-15 |
2015-07-28 |
Bayer Healthcare Llc |
Methods for treating bleeding disorders
|
WO2014153424A1
(en)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
|
BR112016001457A2
(pt)
|
2013-07-25 |
2017-08-29 |
Dana Farber Cancer Inst Inc |
Inibidores de fatores de transcrição e usos dos mesmos
|
WO2015157955A1
(en)
|
2014-04-17 |
2015-10-22 |
Abbvie Inc. |
Heterocyclic btk inhibit ors
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
DK3309174T3
(da)
|
2014-07-11 |
2022-06-07 |
Ventana Med Syst Inc |
ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
|
BR112017007072A2
(pt)
|
2014-10-06 |
2018-01-30 |
Flatley Discovery Lab Llc |
compostos de triazolopiridina e métodos para o tratamento de fibrose cística
|
CN106852149B
(zh)
|
2014-10-10 |
2021-08-27 |
依奈特制药公司 |
Cd73阻断
|
US20180030144A1
(en)
|
2014-10-10 |
2018-02-01 |
Innate Pharma |
Cd73 blockade
|
BR112017009398A2
(pt)
|
2014-11-10 |
2018-05-15 |
Medimmune Ltd |
moléculas de ligação específicas para cd73 e seus usos
|
GB2538120A
(en)
|
2014-11-11 |
2016-11-09 |
Medimmune Ltd |
Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
|
TWI758928B
(zh)
|
2014-11-21 |
2022-03-21 |
美商必治妥美雅史谷比公司 |
抗cd73抗體及其用途
|
MA41090A
(fr)
|
2014-12-03 |
2017-10-10 |
H Lundbeck As |
Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
|
WO2016129684A1
(ja)
|
2015-02-12 |
2016-08-18 |
日産化学工業株式会社 |
縮合複素環化合物及び有害生物防除剤
|
ES2751669T3
(es)
*
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
AU2016229268B2
(en)
|
2015-03-06 |
2020-09-10 |
Pharmakea, Inc. |
Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
|
MX2017012699A
(es)
|
2015-04-03 |
2018-02-09 |
Incyte Corp |
Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
|
HUE056201T2
(hu)
|
2015-07-30 |
2022-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
ES2928164T3
(es)
|
2015-10-19 |
2022-11-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
CA3005727A1
(en)
|
2015-11-19 |
2017-05-26 |
Incyte Corporation |
Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
|
CN109154611B
(zh)
|
2015-12-09 |
2022-04-08 |
科尔沃斯制药股份有限公司 |
人源化抗cd73抗体
|
WO2017106634A1
(en)
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
|
PE20230731A1
(es)
|
2015-12-22 |
2023-05-03 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
EP3393475A4
(en)
|
2015-12-24 |
2019-08-14 |
Corvus Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
AU2017222417B2
(en)
|
2016-02-24 |
2020-07-09 |
Pfizer Inc. |
Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
ES2947636T3
(es)
|
2016-03-16 |
2023-08-14 |
Kura Oncology Inc |
Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
ES2905980T3
(es)
|
2016-05-26 |
2022-04-12 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
PE20190731A1
(es)
|
2016-06-20 |
2019-05-23 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
WO2018004478A1
(en)
|
2016-06-29 |
2018-01-04 |
Hayat Kimya San. A. Ş. |
An improved method of soft nonwoven fabric production
|
US10793636B2
(en)
|
2016-07-11 |
2020-10-06 |
Corvus Pharmaceuticals, Inc. |
Anti-CD73 antibodies
|
ES2930092T3
(es)
|
2016-07-14 |
2022-12-07 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
CR20190101A
(es)
|
2016-09-02 |
2019-07-04 |
Ironwood Pharmaceuticals Inc |
Estimuladores de sgc
|
EP3556773A4
(en)
|
2016-12-13 |
2020-08-19 |
Astellas Pharma Inc. |
ANTIBODIES TO HUMAN CD73
|
ES2934789T3
(es)
|
2016-12-16 |
2023-02-27 |
Pfizer |
Agonistas del receptor glp-1 y usos del mismo
|
BR112019012957A2
(pt)
|
2016-12-22 |
2019-11-26 |
Incyte Corp |
derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
MY197635A
(en)
|
2016-12-22 |
2023-06-29 |
Incyte Corp |
Benzooxazole derivatives as immunomodulators
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
IL296456A
(en)
|
2017-01-23 |
2022-11-01 |
Revolution Medicines Inc |
Bicyclics as allosteric shp2 inhibitors
|
EP4050030A1
(en)
|
2017-01-24 |
2022-08-31 |
I-Mab Biopharma US Limited |
Anti-cd73 antibodies and uses thereof
|
CN108467386B
(zh)
*
|
2017-02-23 |
2020-11-17 |
江苏恒瑞医药股份有限公司 |
稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用
|
JP7111733B2
(ja)
*
|
2017-03-16 |
2022-08-02 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
ヘテロアリール[4,3-c]ピリミジン-5-アミン誘導体、その製造方法、およびその医薬の使用
|
US20210107989A1
(en)
|
2017-04-04 |
2021-04-15 |
Corvus Pharmaceuticals, Inc. |
Methods for treating cd73hi tumors
|
CN110446712B
(zh)
|
2017-04-07 |
2021-09-14 |
南京明德新药研发有限公司 |
作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
|
CA3063344A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Novel cd73 antibody, preparation and uses thereof
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
WO2019002606A1
(en)
|
2017-06-30 |
2019-01-03 |
Selvita S.A. |
ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS
|
CN109535161B
(zh)
|
2017-09-22 |
2021-09-03 |
江苏恒瑞医药股份有限公司 |
三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
|
CN111225917A
(zh)
|
2017-10-24 |
2020-06-02 |
拜耳股份公司 |
取代咪唑并吡啶酰胺及其用途
|
BR112020008888A2
(pt)
|
2017-11-16 |
2020-10-20 |
Novartis Ag |
terapias de combinação
|
WO2019152687A1
(en)
|
2018-01-31 |
2019-08-08 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
WO2019152678A1
(en)
|
2018-01-31 |
2019-08-08 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
SG11202007739XA
(en)
|
2018-02-17 |
2020-09-29 |
Astrazeneca Ab |
Arginase inhibitors and methods of use thereof
|
CN112384515A
(zh)
|
2018-02-27 |
2021-02-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
|
WO2019170131A1
(zh)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
|
MX2020009366A
(es)
|
2018-03-09 |
2020-10-14 |
Phanes Therapeutics Inc |
Anticuerpos anti-cd73 y usos de los mismos.
|
BR112020017382A2
(pt)
|
2018-03-09 |
2021-01-26 |
Agenus Inc. |
anticorpos anti-cd73 e métodos de uso dos mesmos
|
HRP20230090T1
(hr)
|
2018-03-30 |
2023-03-17 |
Incyte Corporation |
Heterociklički spojevi kao imunomodulatori
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
MX2020010604A
(es)
|
2018-04-12 |
2020-10-20 |
Bristol Myers Squibb Co |
Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
|
CN112752756A
(zh)
|
2018-05-11 |
2021-05-04 |
因赛特公司 |
作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
KR20210030366A
(ko)
|
2018-06-20 |
2021-03-17 |
인사이트 코포레이션 |
항-pd-1 항체 및 이의 용도
|
EP3818063A1
(en)
|
2018-07-05 |
2021-05-12 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
EP3820474A4
(en)
|
2018-07-10 |
2022-03-23 |
Nikang Therapeutics, Inc. |
ADENOSINE RECEPTOR BINDING COMPOUNDS
|
CA3104928A1
(en)
|
2018-08-13 |
2020-02-20 |
F. Hoffmann-La Roche Ag |
New heterocyclic compounds as monoacylglycerol lipase inhibitors
|
SG11202012222TA
(en)
|
2018-08-13 |
2021-01-28 |
Hoffmann La Roche |
New heterocyclic compounds as monoacylglycerol lipase inhibitors
|
GB201813678D0
(en)
|
2018-08-22 |
2018-10-03 |
Keybioscience Ag |
Acylated calcitonin mimetics
|
MX2021002042A
(es)
|
2018-08-22 |
2021-04-28 |
Astrazeneca Ab |
Inhibidores de arginasa y sus metodos de uso.
|
AR116315A1
(es)
|
2018-09-12 |
2021-04-21 |
Dizal Jiangsu Pharmaceutical Co Ltd |
Compuestos de triazolo-pirimidina y usos de los mismos
|
WO2020069027A1
(en)
|
2018-09-26 |
2020-04-02 |
Kura Oncology, Inc. |
Treatment of hematological malignancies with inhibitors of menin
|
CN111295384B
(zh)
|
2018-10-10 |
2022-08-12 |
江苏豪森药业集团有限公司 |
双环类衍生物抑制剂、其制备方法和应用
|
UY38437A
(es)
|
2018-11-02 |
2020-05-29 |
Aicuris Gmbh & Co Kg |
Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
|
WO2020106560A1
(en)
|
2018-11-20 |
2020-05-28 |
Merck Sharp & Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
CN111511738B
(zh)
|
2018-11-30 |
2023-01-20 |
江苏豪森药业集团有限公司 |
杂芳类衍生物调节剂、其制备方法和应用
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
US11753406B2
(en)
|
2019-08-09 |
2023-09-12 |
Incyte Corporation |
Salts of a PD-1/PD-L1 inhibitor
|
CA3150766A1
(en)
|
2019-08-26 |
2021-03-04 |
Incyte Corporation |
Triazolopyrimidines as a2a / a2b inhibitors
|
AR120109A1
(es)
|
2019-09-30 |
2022-02-02 |
Incyte Corp |
Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
|
PE20230407A1
(es)
|
2019-11-11 |
2023-03-07 |
Incyte Corp |
Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
|
MX2022008208A
(es)
|
2020-01-03 |
2022-10-21 |
Incyte Corp |
Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
|
CN115135341A
(zh)
|
2020-01-03 |
2022-09-30 |
因赛特公司 |
抗cd73抗体及其用途
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|
MX2023005362A
(es)
|
2020-11-06 |
2023-06-22 |
Incyte Corp |
Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
|
EP4271384A1
(en)
|
2020-12-29 |
2023-11-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|